Literature DB >> 26847803

Long-term survival in patients with pancreatic ductal adenocarcinoma.

Alexander P Stark1, Greg D Sacks2, Matthew M Rochefort2, Timothy R Donahue1, Howard A Reber1, James S Tomlinson2, David W Dawson3, Guido Eibl1, O Joe Hines4.   

Abstract

BACKGROUND: Long-term survival (LTS) is uncommon for patients with pancreatic ductal adenocarcinoma (PDAC). We sought to identify factors that predict 10-year, LTS after resection of PDAC.
METHODS: We identified all patients with PDAC who underwent resection at UCLA after 1990 and included all patients eligible for observed LTS (1/1/1990-12/31/2004). An independent pathologist reconfirmed the diagnosis of PDAC in patients with LTS. Logistic regression was used to predict LTS on the basis of patient and tumor characteristics.
RESULTS: Of 173 included patients, 53% were male, median age at diagnosis was 66 years, and median survival was 23 months. The rate of observed LTS was 12.1% (n = 21). Age, sex, number of lymph nodes evaluated, margin status, lymphovascular invasion, and adjuvant chemotherapy and radiation were not associated with LTS. The following were associated with LTS on bivariate analysis: low AJCC stage (Ia, Ib, IIa) (P = .034), negative lymph node status (P = .034), low grade (well-, moderately-differentiated) (P = .001), and absence of perineural invasion (P = .019). Only low grade (odds ratio 7.17, P = .012) and absent perineural invasion (odds ratio 3.28, P = .036) were independently associated with increased odds of LTS. Our multivariate model demonstrated good discriminatory power for LTS, as indicated by a c-statistic of 0.7856.
CONCLUSION: Absence of perineural invasion and low tumor grade were associated with greater likelihood of LTS. Understanding the tumor biology of LTS may provide critical insight into a disease that is typically marked by aggressive behavior and limited survival.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26847803      PMCID: PMC4856542          DOI: 10.1016/j.surg.2015.12.024

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  36 in total

1.  Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma.

Authors:  Kazuaki Shimada; Yoshihiro Sakamoto; Satoshi Nara; Minoru Esaki; Tomoo Kosuge; Nobuyoshi Hiraoka
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

2.  Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.

Authors:  Timothy R Donahue; William H Isacoff; O Joe Hines; James S Tomlinson; James J Farrell; Yasser M Bhat; Edward Garon; Barbara Clerkin; Howard A Reber
Journal:  Arch Surg       Date:  2011-07

3.  Pancreatic cancer surgery in the new millennium: better prediction of outcome.

Authors:  Werner Hartwig; Thilo Hackert; Ulf Hinz; Alexander Gluth; Frank Bergmann; Oliver Strobel; Markus W Büchler; Jens Werner
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

4.  R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use.

Authors:  Bettina M Rau; Katharina Moritz; Sarah Schuschan; Guido Alsfasser; Friedrich Prall; Ernst Klar
Journal:  Surgery       Date:  2012-07-03       Impact factor: 3.982

5.  Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions.

Authors:  Mustapha Adham; Daniel Jaeck; Joël Le Borgne; Elie Oussoultzouglou; Marie-Pierre Chenard-Neu; Jean-François Mosnier; Jean-Yves Scoazec; Françoise Mornex; Christian Partensky
Journal:  Pancreas       Date:  2008-11       Impact factor: 3.327

6.  Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging?

Authors:  Nabil Wasif; Clifford Y Ko; James Farrell; Zev Wainberg; Oscar J Hines; Howard Reber; James S Tomlinson
Journal:  Ann Surg Oncol       Date:  2010-04-27       Impact factor: 5.344

7.  Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.

Authors:  Marianne Sinn; Jana K Striefler; Bruno V Sinn; Daniel Sallmon; Sven Bischoff; Jens M Stieler; Uwe Pelzer; Marcus Bahra; Peter Neuhaus; Bernd Dörken; Carsten Denkert; Hanno Riess; Helmut Oettle
Journal:  J Surg Oncol       Date:  2013-08-23       Impact factor: 3.454

8.  The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Authors:  Hartwig Riediger; Tobias Keck; Ulrich Wellner; Axel zur Hausen; Ulrich Adam; Ulrich T Hopt; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2009-05-06       Impact factor: 3.452

9.  Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.

Authors:  Matthew M Rochefort; Jacob S Ankeny; Brian E Kadera; Graham W Donald; William Isacoff; Zev A Wainberg; O Joe Hines; Timothy R Donahue; Howard A Reber; James S Tomlinson
Journal:  Ann Surg Oncol       Date:  2013-08-14       Impact factor: 5.344

10.  Association of diabetes and perineural invasion in pancreatic cancer.

Authors:  Ibrahim Halil Sahin; Mohamed A Shama; Motofumi Tanaka; James L Abbruzzese; Steven A Curley; Manal Hassan; Donghui Li
Journal:  Cancer Med       Date:  2012-10-30       Impact factor: 4.452

View more
  33 in total

1.  Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.

Authors:  Douglas S Swords; Sean J Mulvihill; Matthew A Firpo; Courtney L Scaife
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

2.  A Prognostic Score for Predicting Survival in Patients With Pancreatic Head Adenocarcinoma and Distal Cholangiocarcinoma.

Authors:  Edoardo Maria Muttillo; Antonio Ciardi; Paolina Saullo; Raffaele Troiano; Gabriele Masselli; Marianna Guida; Alessandra Tortora; Isabella Sperduti; Giulio Marinello; Piero Chirletti; Roberto Caronna
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  Pathological analysis of the superior mesenteric artery boundary in preoperative computed tomography of resectable pancreatic head adenocarcinoma.

Authors:  Meng Lu; Chun-Hui Yuan; Ling-Fu Zhang; Lian-Yuan Tao; Ying Peng; Li-Mei Guo; Gang Li; Dian-Rong Xiu
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

4.  Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Authors:  Martin Graversen; Sönke Detlefsen; Jon Kroll Bjerregaard; Per Pfeiffer; Michael Bau Mortensen
Journal:  Clin Exp Metastasis       Date:  2017-05-17       Impact factor: 5.150

5.  Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis.

Authors:  Marc A Attiyeh; Jayasree Chakraborty; Alexandre Doussot; Liana Langdon-Embry; Shiana Mainarich; Mithat Gönen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; William R Jarnagin; T Peter Kingham; Peter J Allen; Amber L Simpson; Richard K Do
Journal:  Ann Surg Oncol       Date:  2018-01-29       Impact factor: 5.344

6.  Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma.

Authors:  Nayra S Amaral; Vivian Resende; José Sebastião Dos Santos; Luiz Felipe Lima; Debora C Moraes; Eitan Friedman; Luiz DE Marco; Luciana Bastos-Rodrigues
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

7.  Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI.

Authors:  Derek J Erstad; Mozhdeh Sojoodi; Martin S Taylor; Veronica Clavijo Jordan; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs; Christian T Farrar; Andrea L Axtell; Nicholas J Rotile; Chloe Jones; Katherine A Graham-O'Regan; Diego S Ferreira; Theodoros Michelakos; Filippos Kontos; Akhil Chawla; Shen Li; Sarani Ghoshal; Yin-Ching Iris Chen; Gunisha Arora; Valerie Humblet; Vikram Deshpande; Motaz Qadan; Nabeel Bardeesy; Cristina R Ferrone; Michael Lanuti
Journal:  Clin Cancer Res       Date:  2020-07-01       Impact factor: 12.531

8.  Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy.

Authors:  Andreas Minh Luu; Orlin Belyaev; Philipp Höhn; Michael Praktiknjo; Monika Janot; Waldemar Uhl; Chris Braumann
Journal:  J Gastrointest Oncol       Date:  2021-04

9.  Development and multicenter validation of a CT-based radiomics signature for discriminating histological grades of pancreatic ductal adenocarcinoma.

Authors:  Na Chang; Lingling Cui; Yahong Luo; Zhihui Chang; Bing Yu; Zhaoyu Liu
Journal:  Quant Imaging Med Surg       Date:  2020-03

10.  Undifferentiated Pancreatic Carcinoma With Osteoclast-Like Giant Cells and Associated Ductal Adenocarcinoma With Focal Signet-Ring Features.

Authors:  Oluwaseyi Olayinka; Gagandeep Kaur; Gunjan Gupta
Journal:  Cureus       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.